SFG
BCLI

Socha Financial Group’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Socha Financial Group’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-825
Closed -$6.99K – 21
2024
Q1 		$6.99K Hold
825
– – ﹤0.01% 30
2023
Q4 		$3.38K Hold
825
– – ﹤0.01% 30
2023
Q3 		$2.48K Hold
825
– – ﹤0.01% 28
2023
Q2 		$25.5K Buy
+825
New +$34.2K 0.01% 28

Other funds holding BCLI

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LWM
Liberty Wealth Management Oakland, California $800M AUM 20.44% 1-Year Est. Return
WCG
Weaver Consulting Group Huntington Beach, California $420M AUM 14.29% 1-Year Est. Return
AHB
Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Socha Financial Group's BCLI Position: Q2 2024 in Review

Socha Financial Group sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q2 2024, closing a stake of 825 shares — an estimated $6.99K sold.

Socha Financial Group first reported a position in BCLI in Q2 2023 and held it in 4 quarters. The position peaked at $25.5K in Q2 2023. 48 funds tracked by Wall St. Rank hold BCLI as of Q2 2024.

  • Socha Financial Group reported no remaining BRAINSTORM CELL THERAPUTC position as of Q2 2024 after selling out during the quarter.
  • Socha Financial Group sold 825 BRAINSTORM CELL THERAPUTC shares in Q2 2024, an estimated $6.99K.
  • Socha Financial Group first reported a position in BRAINSTORM CELL THERAPUTC in Q2 2023 and held it in 4 quarters.
  • Socha Financial Group's BRAINSTORM CELL THERAPUTC position peaked at $25.5K in Q2 2023.
  • 48 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q2 2024.

Based on Socha Financial Group's 13F filing for Q2 2024, filed 31 Jul 2024.